WASHINGTON, Dec. 18, 2015 /PRNewswire/ -- Vanda
Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), announced today that
Kenneth Bate, an independent
biotechnology industry consultant, has joined Vanda's Board of
Directors. In connection with Mr. Bate's election, the Board has
increased the number of directors to seven.
"I would like to personally welcome Ken to our Board," said
Mihael H. Polymeropoulos, M.D.,
President and Chief Executive Officer of Vanda. "We are very
fortunate to have someone with his breadth of pharmaceutical
industry and leadership experience on our Board as we continue to
drive Vanda on a strong growth trajectory."
Mr. Bate is an experienced biotechnology executive having led
companies at various stages of development. Mr. Bate currently
serves as an independent biotechnology industry consultant, which
he has done since May 2009. Mr. Bate
previously served as President and Chief Executive Officer of
Archemix, Inc. from May 2009 to
January 2012. From 2006 to 2009, Mr. Bate served in various
positions at Nitromed, Inc., most recently as President and Chief
Executive Officer. From 2002 to 2005, Mr. Bate served as
Chief Financial Officer of Millennium Pharmaceuticals
Inc. Mr. Bate served as the Chairman of the Board of
Cubist Pharmaceuticals, Inc. from 2011 to 2015. He currently is a
director of BioMarin Pharmaceutical Inc., AVEO Pharmaceuticals,
Inc., Genocea Biosciences, Inc., Catabasis Pharmaceuticals, Inc.
Epizyme, Inc. and TransMedics, Inc. Mr. Bate received his
B.A. in Chemistry from Williams College
and his M.B.A. from the Wharton School of the University of Pennsylvania.
About Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company
focused on the development and commercialization of products for
the treatment of central nervous system disorders. For more on
Vanda, please visit www.vandapharma.com.
CAUTIONARY NOTE REGARDING FORWARD LOOKING STATEMENTS
Various statements in this release, including, without limitation,
statements regarding Vanda's global strategy, are "forward-looking
statements" under the securities laws. Forward-looking statements
are based upon current expectations that involve risks, changes in
circumstances, assumptions and uncertainties. Important factors
that could cause actual results to differ materially from those
reflected in Vanda's forward-looking statements include, among
others, Vanda's assumptions regarding its commercialization efforts
and other factors that are set forth in the "Risk Factors" and
"Management's Discussion and Analysis of Financial Condition and
Results of Operations" sections of Vanda's annual report on
Form 10-K for the fiscal year ended December 31, 2014 and
quarterly report on Form 10-Q for the quarter ended
September 30, 2015, which are on file
with the SEC and available on the SEC's website at www.sec.gov. In
addition to the risks described above and in Vanda's annual report
on Form 10-K and quarterly reports on Form 10-Q, other
unknown or unpredictable factors also could affect Vanda's results.
There can be no assurance that the actual results or developments
anticipated by Vanda will be realized or, even if substantially
realized, that they will have the expected consequences to, or
effects on, Vanda. Therefore, no assurance can be given that the
outcomes stated in such forward-looking statements and estimates
will be achieved.
All written and verbal forward-looking statements attributable
to Vanda or any person acting on its behalf are expressly qualified
in their entirety by the cautionary statements contained or
referred to herein. Vanda cautions investors not to rely too
heavily on the forward-looking statements Vanda makes or that are
made on its behalf. The information in this release is provided
only as of the date of this release, and Vanda undertakes no
obligation, and specifically declines any obligation, to update or
revise publicly any forward-looking statements, whether as a result
of new information, future events or otherwise.
Corporate Contact:
Jim
Kelly
Senior Vice President and Chief Financial
Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428
jim.kelly@vandapharma.com
Media Contact:
Laney Landsman
Assistant
Vice President
Makovsky
(212) 508-9643
llandsman@makovsky.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/kenneth-bate-joins-the-board-of-directors-of-vanda-pharmaceuticals-300195079.html
SOURCE Vanda Pharmaceuticals Inc.